Form 8-K Sarepta Therapeutics, For: May 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho
May 3, 2021 1:43 PM EDTMizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.
Yang commented, "The data was in line with our "base case"... More
